Citations

Clear

1011 citation(s) found for "Barry, WT".

Ventilatory Assistance Before Umbilical Cord Clamping in Extremely Preterm Infants
Petroni, Gina R. , Varhegyi, Nikole, Strand, Marya L. , Josephsen, Justin , Niermeyer, Susan , Barry, James S. , Fang, Jennifer L. , Thomas, Sumesh , Kane, Andrea F., Byrne, Bobbi J., Underwood, Mark A. , Poulain, Francis R., Law, Brenda Hiu Yan , Gorman, Terri, Leone, Tina A. , Bulas, Dorothy , Epelman, Mónica , Chisholm, Christian A., Kattwinkel, John, Duda, Gina M, Thielen, Monika, Liedl, Lavonne M., Amsbaugh, Amy, Lamprecht, Amy, Berlinski, Carolyn S, Johnson, Jacque-Lynne F, Irvine, Leigh , Ciorogariu-Ivan, Anna-Maria, Pesavento, Rosa R, Fray, Caroline , Athaide, Melba, Fairchild, Karen D. , Warren, Jamie B. , Rincon, Monica P. , Travers, Colm P. , Carlo, Waldemar A. , Kline‐Fath, Beth M. , Hawkins, Melissa, Ciorogariu‐Ivan, Anna‐Maria

Mayo Clinic

JAMA Network Open | May 17, 2024 | Volume: 7 | Issue: 5 | Pages: e2411140

10.1001/jamanetworkopen.2024.11140 | PMID 38758557 Get It

ImportanceProviding assisted ventilation during delayed umbilical cord clamping may improve outcomes for extremely preterm infants.ObjectiveTo determine whether assisted ventilation in extremely preterm infants (23 0/7 to 28 6/7 weeks’ gestational age [GA]) followed by cord clamping reduces intraventricular hemorrhage (IVH) or early death.Design, Setting, and ParticipantsThis phase 3, 1:1, parallel-stratified randomized clinical trial conducted at 12 perinatal centers across the US and Canada from September 2, 2016, through February 21, 2023, assessed IVH and early death outcomes of extremely preterm infants randomized to receive 120 seconds of assisted ventilation followed by cord clamping vs delayed cord clamping for 30 to 60 seconds with ventilatory assistance afterward. Two analysis cohorts, not breathing well and breathing well, were specified a priori based on assessment of breathing 30 seconds after birth.InterventionAfter birth, all infants received stimulation and suctioning if needed. From 30 to 120 seconds, infants randomized to the intervention received continuous positive airway pressure if breathing well or positive-pressure ventilation if not, with cord clamping at 120 seconds. Control infants received 30 to 60 seconds of delayed cord clamping followed by standard resuscitation.Main Outcomes and MeasuresThe primary outcome was any grade IVH on head ultrasonography or death before day 7. Interpretation by site radiologists was confirmed by independent radiologists, all masked to study group. To estimate the association between study group and outcome, data were analyzed using the stratified Cochran-Mantel-Haenszel test for relative risk (RR), with associations summarized by point estimates and 95% CIs.ResultsOf 1110 women who consented to participate, 548 were randomized and delivered infants at GA less than 29 weeks. A total of 570 eligible infants were enrolled (median [IQR] GA, 26.6 [24.9-27.7] weeks; 297 male [52.1%]). Intraventricular hemorrhage or death occurred in 34.9% (97 of 278) of infants in the intervention group and 32.5% (95 of 292) in the control group (adjusted RR, 1.02; 95% CI, 0.81-1.27). In the prespecified not-breathing-well cohort (47.5% [271 of 570]; median [IQR] GA, 26.0 [24.7-27.4] weeks; 152 male [56.1%]), IVH or death occurred in 38.7% (58 of 150) of infants in the intervention group and 43.0% (52 of 121) in the control group (RR, 0.91; 95% CI, 0.68-1.21). There was no evidence of differences in death, severe brain injury, or major morbidities between the intervention and control groups in either breathing cohort.Conclusions and RelevanceThis study did not show that providing assisted ventilation before cord clamping in extremely preterm infants reduces IVH or early death. Additional study around the feasibility, safety, and efficacy of assisted ventilation before cord clamping may provide additional insight.Trial RegistrationClinicalTrials.gov Identifier: NCT02742454
Mitral Regurgitation and Heart Failure with Preserved Ejection Fraction: Should we Treat the Muscle, the Valve, or Both?
Riccardi, Mauro , Borlaug, Barry A. , Inciardi, Riccardo M.

Mayo Clinic

European Journal of Heart Failure | May 13, 2024 | Volume: 26 | Issue: 6 | Pages: 1443-1445

10.1002/ejhf.3288 | PMID 38740731 Get It

Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Shah, Sanjiv J, Borlaug, Barry A. , Butler, Javed , Davies, Melanie J. , Kitzman, Dalane W. , Petrie, Mark C. , Verma, Subodh, Patel, Shachi, Einfeldt, Mette Nygaard , Jensen, Thomas, Rasmussen, Søren, Ben‐Gal, Tuvia , Kosiborod, Mikhail , Borlaug, Barry A , Butler, Javed , Asleh, Rabea , Kosiborod, Mikhail N , Petrie, Mark C , Shah, Sanjiv J , Sharma, Kavita , Verma, Subodh , Chinnakondepalli, Khaja , Asleh, Rabea , Gal, Tuvia Ben

Mayo Clinic

European Heart Journal | May 13, 2024 | Volume: 45 | Issue: 35 | Pages: 3254-3269

10.1093/eurheartj/ehae322 | PMID 38739118 Get It

Abstract Background and Aims In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. Methods In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM trials (n = 1145), which randomized participants with HFpEF and body mass index ≥ 30 kg/m2 to once weekly semaglutide 2.4 mg or placebo for 52 weeks, we examined whether efficacy and safety endpoints differed by baseline diuretic use, as well as the effect of semaglutide on loop diuretic use and dose changes over the 52-week treatment period. Results At baseline, across no diuretic (n = 220), non-loop diuretic only (n = 223), and loop diuretic [<40 (n = 219), 40 (n = 309), and >40 (n = 174) mg/day furosemide equivalents] groups, there was progressively higher prevalence of hypertension and atrial fibrillation; and greater severity of obesity and heart failure. Over 52 weeks of treatment, semaglutide had a consistent beneficial effect on change in body weight across diuretic use categories (adjusted mean difference vs. placebo ranged from −8.8% [95% confidence interval (CI) −10.3, −6.3] to −6.9% [95% CI −9.1, −4.7] from no diuretics to the highest loop diuretic dose category; interaction P = .39). Kansas City Cardiomyopathy Questionnaire clinical summary score improvement was greater in patients on loop diuretics compared to those not on loop diuretics (adjusted mean difference vs. placebo: +9.3 [6.5; 12.1] vs. +4.7 points [1.3, 8.2]; P = .042). Semaglutide had consistent beneficial effects on all secondary efficacy endpoints (including 6 min walk distance) across diuretic subgroups (interaction P = .24–.92). Safety also favoured semaglutide vs. placebo across the diuretic subgroups. From baseline to 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs. a 2.4% increase in the placebo group (P < .0001). Semaglutide (vs. placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67 [95% CI 1.70, 4.18]) and less likely dose increase (OR 0.35 [95% CI 0.23, 0.53]; P < .001 for both) from baseline to 52 weeks. Conclusions In patients with obesity-related HFpEF, semaglutide improved heart failure-related symptoms and physical limitations across diuretic use subgroups, with more pronounced benefits among patients receiving loop diuretics at baseline. Reductions in weight and improvements in exercise function with semaglutide vs. placebo were consistent in all diuretic use categories. Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks. Clinical Trial Registration NCT04788511 and NCT04916470.
Artificial Intelligence Algorithms for Expert Identification in Medical Domains: A Scoping Review
Borna, Sahar , Makarova, Svetlana , Parte, Yogesh, Haider, Clifton R. , Sehgal, Ajai , Leibovich, Bradley C. , Forte, Antonio J. , Barry, Barbara , Sehgal, Ajai , Forte, Antonio Jorge , Borna, Sahar , Barry, Barbara , Makarova, Svetlana

Mayo Clinic

European Journal of Investigation in Health, Psychology and Education | May 2, 2024 | Volume: 14 | Issue: 5 | Pages: 1182-1196

10.3390/ejihpe14050078 | PMID 38785576 Get It

With abundant information and interconnectedness among people, identifying knowledgeable individuals in specific domains has become crucial for organizations. Artificial intelligence (AI) algorithms have been employed to evaluate the knowledge and locate experts in specific areas, alleviating the manual burden of expert profiling and identification. However, there is a limited body of research exploring the application of AI algorithms for expert finding in the medical and biomedical fields. This study aims to conduct a scoping review of existing literature on utilizing AI algorithms for expert identification in medical domains. We systematically searched five platforms using a customized search string, and 21 studies were identified through other sources. The search spanned studies up to 2023, and study eligibility and selection adhered to the PRISMA 2020 statement. A total of 571 studies were assessed from the search. Out of these, we included six studies conducted between 2014 and 2020 that met our review criteria. Four studies used a machine learning algorithm as their model, while two utilized natural language processing. One study combined both approaches. All six studies demonstrated significant success in expert retrieval compared to baseline algorithms, as measured by various scoring metrics. AI enhances expert finding accuracy and effectiveness. However, more work is needed in intelligent medical expert retrieval.
Pulsatile Loading Affects Right Ventricular Function in Pulmonary Hypertension Due to Chronic Lung Disease
Mendoza, Marco Patricio Bravo, Beck, Gerald J. , Hill, Nicholas S. , Insel, Michael , Larive, Brett , Yu, Shan, Group, PVDOMICS Study, Yu, Shilin , Borlaug, Barry A. , Frantz, Robert P. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Mukherjee, Monica , Rosenzweig, Erika B. , Yu, S., Rischard, Franz

Mayo Clinic

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7360-A7360

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7360 Get It

Associations of COPD and Related Outcomes With COVID-19 Hospitalization or Death: The C4R, Copdgene, and Spiromics Studies
Rusk, A.M., Bowler, R.P., Margaret, D., Elkind, Mitchell S.V. , Ramachandran, V., Woodruff, Prescott G. , Garudadri, S., McKleroy, William , Ortega, Victor E. , Balte, Pallavi , Allen, Norrina B. , Barr, R. Graham , Regan, Elizabeth Anne , Cole, Shelley A. , Couper, David , Demmer, Ryan T. , Kaplan, Robert C. , Lee, Joyce , Post, Wendy S. , Ramachandran, V., Schwartz, David A. , Tracy, Russell P. , Wenzel, Sally E. , Xanthakis, Vanessa , Make, Barry J. , Oelsner, Elizabeth C.

Mayo Clinic

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6817-A6817

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6817 Get It

Association of Pre-pandemic High Attenuation Areas on Lung CT and COVID-19 Hospitalization and Death: The C4R Study
Kim, J. , Balte, P., Sun, Yifei , Smith, B.M. , Podolanczuk, A., Lee, J.S., Washko, G.R., Hunninghake, G.M., Regan, E.A., Woodruff, P., Ortega, Victor E. , Lynch, David A. , Laine, Andrew F. , Hoffman, E.A., Oelsner, E., Hermann, E.A. , Schwartz, David A. , Stukovsky, Karen Hinckley , Make, Barry J. , Hoffman, E.A., Barr, R. Graham

Mayo Clinic

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6814-A6814

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6814 Get It

Abstract 9925: Impaired Cardiac Output and Peripheral Reserve Predict Morbidity and Mortality in Heart Failure and Preserved Ejection Fraction
Sorimachi, Hidemi, Omote, Kazunori , Verbrugge, Frederik H. , Reddy, Yogesh N.V. , Omar, Massar , Obokata, Masaru , Borlaug, Barry A.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9925 Get It

Introduction: Reduced peak oxygen consumption (VO 2 ) is common and associated with adverse outcomes in patients with heart failure (HF) and preserved ejection fraction (HFpEF). According to the Fick principle, VO 2 is equal to the product of cardiac output (CO) and arterial-venous O 2 difference (AVO 2 diff). Patients with HFpEF display abnormalities each component, but no study has yet evaluated their prognostic impacts. Methods: Patients with HFpEF (n=501) and controls without HF (n=207) underwent invasive hemodynamic exercise testing with expired gas analysis and clinical follow up for the composite event of HF hospitalization or death. Results: Compared to controls, patients with HFpEF displayed slightly lower CO at rest with higher pulmonary capillary wedge pressure (PCWP). On exercise, subjects with HFpEF displayed blunted increases in CO and greater increase in PCWP (Figure A). As compared with controls, the slope of the increase in CO relative to VO 2 was lower in HFpEF (6.4 ± 3.3 vs 5.4 ± 3.2 L/L; P =0.0004), while augmentation in AVO 2 diff relative to VO 2 was greater in HFpEF (7.7 ± 5.4 vs 10.0 ± 5.6 min/dL; P <0.0001). Over a median 2.8 (1.1-4.6) years of follow up, 101 patients experienced the composite event. Patients with CO reserve below the median and increases in AVO 2 diff below median displayed higher risk of the composite endpoint (Figure B-C). After adjustments for age, sex, BMI, atrial fibrillation, LV mass, and EF, CO reserve remained strongly associated with the primary outcome (HR [95%CI] = 0.51 [0.38-0.68]; P <0.0001, per 1 SD increase) and the change of AVO 2 diff remained significant, but was less predictive (HR [95%CI] = 0.74 [0.60-0.92]; P =0.007, per 1 SD increase) in patients with HFpEF. Conclusions: Impaired ability to augment CO and peripheral O 2 delivery are associated with increasing risk of adverse events in HFpEF. Further study is required to identify therapeutic interventions targeting these hemodynamic perturbations to improve outcomes in HFpEF.
Abstract 9890: HFpEF with Normal Natriuretic Peptides: An Earlier Stage of Disease or Fundamentally Different Phenotype?
Sorimachi, Hidemi, Omote, Kazunori , Obokata, Masaru , Reddy, Yogesh N.V. , Borlaug, Barry A.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9890 Get It

Introduction: Many patients with heart failure with preserved ejection fraction (HFpEF) display normal N-terminal-pro-B type natriuretic peptide (NTproBNP)levels. Mortality and hospitalization rates are lower in this group compared to patients with high NTproBNP, but it remains unclear whether these patients represent a fundamentally different phenotype or an earlier stage of disease. Methods: 213 subjects with HFpEF defined by invasive hemodynamics underwent serial echocardiographic examinations &gt;1 year apart. Clinical, cardiac structural, functional, and hemodynamic characteristics were examined. Results: Exam 2 was performed a median of 3.2 years (IQR 2.2-5.1) following Exam 1. From this cohort, 66 (33%) displayed normal NT-proBNP levels (≤125pg/ml, nBNP) and 147 (67%) displayed high NTproBNP (hBNP). Compared to hBNP, nBNP patients were younger (62±10 vs 71±9 years, p&lt;0.0001) and more obese (35±8 vs 32±7 kg/m 2 , p=0.005). At Exam 1, approximately 50% of nBNP displayed left ventricular (LV) systolic dysfunction defined as LV longitudinal strain (GLS)&lt;16% ( Figure A ) and LA dysfunction defined as left atrial (LA) reservoir strain&lt;26% ( Figure B ), but right ventricular (RV) systolic function as relatively preserved ( Figure C ). At Exam 2, LV, LA, and RV strain decreased in both groups (Panels A-C), with no difference between nBNP and hBNP in the velocity of change (p&gt;0.6 for all). More patients crossed the threshold definition for LV systolic and LA dysfunction in nBNP compared to hBNP ( Figure D and E ), but the prevalence of RV dysfunction increased more in hBNP ( Figure F ). Conclusions: In patients with HFpEF with normal NT-proBNP, biventricular systolic function and LA function deteriorate over time at similar pace. These data suggest that patients with HFpEF are not a fundamentally different disorder, but rather represent an earlier stage of disease that progresses from LV and LA dysfunction in early stages to RV dysfunction in advanced stages.
Abstract 9213: Effect of Ai-Enabled Ecg Screening for Low Ef in Patients With Different Socioeconomic Status
Inselman, Jonathan , Rushlow, David , Thacher, Thomas D., Behnken, Emma , Bernard, Matthew , Rosas, Steven , Akfaly, Abdulla , Misra, Artika , Molling, Paul , Krien, Joseph, Siontis, Konstantinos C. , Friedman, Paul, Kurani, Shaheen , McCoy, Rozalina G. , Foss, Randy , Barry, Barbara , Kapa, Suraj , Gersh, Bernard J. , Pellikka, Patricia A. , López-Jiménez, Francisco , Attia, Zachi I. , Halamka, John , Noseworthy, Peter A. , Yao, Xiaoxi

Mayo Clinic

Circulation | April 23, 2024 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9213 Get It

Introduction: Asymptomatic LV systolic dysfunction is often underdiagnosed, leading to missed opportunities for treatment. In a recently completed pragmatic RCT, an AI algorithm performed on the ECGs ordered as part of routine practice increased early diagnosis of low EF. The current study aimed to understand whether the effectiveness of the AI algorithm integrated into routine care differed by the socioeconomic status of the patient. Methods: The main findings of the RCT were previously published. Clinicians in the intervention group had access to AI results (i.e., a positive or negative screening result, with positive results indicating a high likelihood of low EF). When a positive result was found, clinicians in the intervention group received an alert that encouraged them to order TTE if considered clinically appropriate. Clinicians in the control group did not have access or received alerts. Area deprivation index (ADI) was used to measure area-level social determinants of health. This study included 16,992 patients (control 8,225; intervention: 8,767) who had ECG performed for any indications between 8/5/2019 and 3/31/2020, no prior HF, and a valid address to derive ADI. The primary endpoint was a new diagnosis of EF≤50% within 3 months. Results: The mean age was 60.5±17.6 y. AI increased the diagnosis of low EF in the overall cohort (OR 1.42 [1.13, 1.78], p=0.01). The magnitude of benefit was greater in patients with higher socioeconomic status, e.g., living in an area that is less deprived (OR 1.88 [1.16, 3.05]), with higher median income, lower poverty rate, higher education level, better housing conditions, and higher proportion of white-collar workers, although the interaction was not statistically significant (Figure). Conclusions: AI enables early diagnosis of low EF and the magnitude of benefit might be numerically greater in patients with higher socioeconomic status, possibly due to variations in access to or referral for subsequent testing.